1256490-49-9

Basic information

• Product Name: (S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester
• Synonyms: N-[(R)-(4-Nitrophenoxy)phenoxyphosphinyl]-L-alanine 1-methylethyl ester;L-Alanine, N-[(R)-(4-nitrophenoxy)phenoxyphosphinyl]-, 1-methylethyl ester;(S)-2-[(R)-(4-nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester;(S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylaMino]propionic acid Isopropyl ester
• CAS NO: 1256490-49-9
• Molecular Formula: C₁₈H₂₁N₂O₇P
• Molecular Weight: 408.3477
• Mol File: 1256490-49-9.mol

Chemical Properties

• Melting Point: 42-43℃
• Boiling Point: 514.3±60.0 °C(Predicted)
• Density: 1.302±0.06 g/cm3(Predicted)
• PKA: -5.78±0.70(Predicted)
• CAS DataBase Reference: (S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester(1256490-49-9)
• EPA Substance Registry System: (S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester(1256490-49-9)

Safety Data

• Hazardous Substances Data: 1256490-49-9(Hazardous Substances Data)

Usage

Uses

Used in Biochemical Research:
(S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester is used as a specific antagonist for endothelin receptors in biochemical research for studying the role and function of these receptors in various physiological processes.
Used in Cardiovascular Applications:
In the pharmaceutical industry, (S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester is used as a potent vasoconstrictor agent for the treatment of various cardiovascular diseases, such as hypertension and heart failure.
Used in Neuroprotective Applications:
(S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester is used as a neuroprotective agent in the field of neuroscience for its potential to protect neurons from damage and degeneration, which could be beneficial in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
Used in Drug Delivery Systems:
In the field of drug delivery, (S)-2-[(S)-(4-Nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid Isopropyl ester is used to enhance the lipophilicity of drugs, allowing for improved penetrability in lipid-rich tissues and potentially increasing the bioavailability and therapeutic outcomes of certain medications.

Upstream product

• 777-52-6 1-dichlorophosphoryloxy-4-nitro-benzene 
• 39613-92-8 alanine isopropyl ester hydrochloride 
• 1256490-48-8 (S)-2-[(4-nitro-phenoxy)-phenoxy-phosphorylamino]propionic acid isopropyl ester 
• 793-10-2 p-nitrophenyl phenyl phosphorochloridate 
• 108-95-2 phenol 
• 100-02-7 4-nitro-phenol 
• 770-12-7 O-phenyl phosphorodichloridate 
• 39825-33-7 isopropyl L-alanine 

Downstream Products

• 1190307-88-0 sofosbuvir 
• 1190308-01-0 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy](phenoxy)phosphorylamino}propionic acid isopropyl ester 
• 1384122-46-6 C₂₅H₃₁N₆O₈P 
• 1350735-69-1 C₂₉H₃₇N₆O₉P 

Relevant articles and documents

Enzyme-Catalyzed Kinetic Resolution of Chiral Precursors to Antiviral Prodrugs

Nucleoside analogues are among the most common medications given for the treatment of viral infections and cancers. The therapeutic effectiveness of nucleoside analogues can be dramatically improved by phosphorylation. The ProTide approach was developed u

PROCESS FOR THE PREPARATION OF (Sp)-SOFOSBUVIR AND INTERMEDIATES THEREOF

The present invention is directed towards process for preparation of an optically pure (Sp)-Sofosbuvir of Formula-(I) and its intermediate namely (Sp)-isomer of isopropyl alanyl phosphoramidate of Formula (III) thereof.

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.

Discovery of the first C -nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients

Hepatitis C virus (HCV) infection presents an unmet medical need requiring more effective treatment options. Nucleoside inhibitors (NI) of HCV polymerase (NS5B) have demonstrated pan-genotypic activity and durable antiviral response in the clinic, and they are likely to become a key component of future treatment regimens. NI candidates that have entered clinical development thus far have all been N-nucleoside derivatives. Herein, we report the discovery of a C-nucleoside class of NS5B inhibitors. Exploration of adenosine analogs in this class identified 1′-cyano-2′-C-methyl 4-aza-7,9-dideaza adenosine as a potent and selective inhibitor of NS5B. A monophosphate prodrug approach afforded a series of compounds showing submicromolar activity in HCV replicon assays. Further pharmacokinetic optimization for sufficient oral absorption and liver triphosphate loading led to identification of a clinical development candidate GS-6620. In a phase I clinical study, the potential for potent activity was demonstrated but with high intra- and interpatient pharmacokinetic and pharmacodynamic variability.

METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS

Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.

1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

Synthesis of diastereomerically pure nucleotide phosphoramidates

Prodrugs of therapeutic nucleoside monophosphates masked as phosphoramidate derivatives have become an increasingly important class of antiviral drugs in pharmaceutical research for delivering nucleotides in vitro and in vivo. Conventionally, phosphoramidate derivatives are prepared as a mixture of two diastereomers. We report a class of stable phosphoramidating reagents containing an amino acid ester and two phenolic groups, one unsubstituted and the other with electron-withdrawing substituents. The reagents can be isolated as single diastereomers and reacted with the 5′-hydroxyl group of nucleosides through selective nucleophilic displacement of the substituted phenol to prepare single diastereomer phosphoramidate products. This method has been used to prepare the HCV clinical candidate PSI-7977 in high yield and high diastereomeric purity.

N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION

Disclosed herein are nucleoside phosphoramidates of formula 4 and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. Disclosed is also a process for preparing compound represented by formula 4: (Formula 4) wherein P* represents a chiral phosphorus atom, which comprises: a) reacting an isopropyl-alanate, (Formula A), a di-X'-phenylphosphate, (Formula B), 2'-deoxy-2f-fluoro-2'-C-methyluridine, (Formula 3), and a base to obtain a first mixture comprising 4; wherein X is a conjugate base of an acid, n is 0 or 1, and X' is a halogen, b) reacting the first mixture with a protecting compound to obtain a second mixture comprising 4; and c) optionally subjecting the second mixture to crystallization, chromatography or extraction in order to obtain 4.